Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: yttrium-90 radioembolization Clear all
Not listed No phase listed Observational

Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project

NCT01815879
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases
Interventions
Not listed
Lead sponsor
Andrew Kennedy
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 4, 2026, 3:51 PM EDT
Recruiting Phase 2 Interventional

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

NCT06860815
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver
Interventions
Biopsy, Biospecimen Collection, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging, Transarterial Radioembolization, Yttrium Y 90 Resin Microspheres
Procedure · Biological · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 4, 2026, 3:51 PM EDT
Active, not recruiting Not applicable Interventional

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

NCT05953337
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
Interventions
EYE90 Microspheres Treatment
Device
Lead sponsor
ABK Biomedical
Industry
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Tucson, Arizona • Orange, California • Altamonte Springs, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 4, 2026, 3:51 PM EDT
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 4, 2026, 3:51 PM EDT
Terminated Phase 1 Interventional

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

NCT04108481
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer, Liver Metastasis Colon Cancer, Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Neoplasms, Liver Metastases, Colorectal Carcinoma
Interventions
Durvalumab, Yttrium-90 RadioEmbolization
Drug · Radiation
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 4, 2026, 3:51 PM EDT
Recruiting Phase 1 Interventional

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

NCT05195710
View directory record Official record
Conditions
Metastases
Interventions
Yttrium-90 (Y-90) resin microspheres
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 4, 2026, 3:51 PM EDT
Terminated Not applicable Interventional Results available

Y90 Radiation Segmentectomy vs SBRT for HCC

NCT04235660
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Yttrium-90 Radiation Segmentectomy, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 4, 2026, 3:51 PM EDT
Terminated Early Phase 1 Interventional

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

NCT01730157
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 4, 2026, 3:51 PM EDT
Terminated Not applicable Interventional Results available

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

NCT03059030
View directory record Official record
Conditions
Thrombocytopenia, Cirrhosis
Interventions
TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 4, 2026, 3:51 PM EDT
Withdrawn Not applicable Interventional

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

NCT03300401
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Positron Emission Tomography, Computed Tomography, Yttrium-90 (90Y)
Drug · Device · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 4, 2026, 3:51 PM EDT
Completed No phase listed Observational

Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer

NCT00739167
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 4, 2026, 3:51 PM EDT
Active, not recruiting Phase 1 Interventional

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

NCT03028311
View directory record Official record
Conditions
Metastatic Liver Carcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer
Interventions
Angiography, Computed Tomography, Planar Imaging, Radioembolization, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Yttrium Y 90 Resin Microspheres
Procedure · Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 4, 2026, 3:51 PM EDT
Not yet recruiting Phase 1 Interventional

Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

NCT07365839
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Arm 1 cemiplimab, Arm 2 cemiplimab and fianlimab
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 4, 2026, 3:51 PM EDT
Not listed Early Phase 1 Interventional

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

NCT03099564
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Pembrolizumab, Y90 radioembolization
Drug · Device
Lead sponsor
Ashwin Somasundaram
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 4, 2026, 3:51 PM EDT
Withdrawn Phase 1 Interventional

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

NCT03117855
View directory record Official record
Conditions
Bile Duct Adenocarcinoma, Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma
Interventions
Capecitabine, Laboratory Biomarker Analysis, Radioembolization
Drug · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 4, 2026, 3:51 PM EDT
Completed Not applicable Interventional Results available

Impact of Y90 Radiation Segmentectomy on HCC

NCT03248375
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Radiation Segmentectomy
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 4, 2026, 3:51 PM EDT
Completed No phase listed Observational

Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC

NCT04459468
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Lipiodol
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 4, 2026, 3:51 PM EDT
Recruiting Phase 2 Interventional

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

NCT06627244
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Interventions
Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 4, 2026, 3:51 PM EDT
Recruiting Not applicable Interventional

PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System

NCT07444645
View directory record Official record
Conditions
Tumor, Liver
Interventions
Y90 Microsphere Therapy
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 3:51 PM EDT
Terminated No phase listed Observational

Prospective Tumor Response Evaluation

NCT02787954
View directory record Official record
Conditions
Hepatocellular Cancer, Metastatic Liver Cancer
Interventions
TACE, Y-90, MWA, IRE
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 4, 2026, 3:51 PM EDT
Not listed Phase 2 Interventional

Definitive Therapy for Oligometastatic Solid Malignancies

NCT01898962
View directory record Official record
Conditions
Stage IV or Recurrent Carcinoma or Sarcoma
Interventions
Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose, Subtotal surgical removal plus ablative radiation dose, Radioembolization
Procedure · Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • Boulder, Colorado • Littleton, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 4, 2026, 3:51 PM EDT
Terminated Early Phase 1 Interventional

Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

NCT04150874
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
Lumason®
Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 4, 2026, 3:51 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

NCT03203837
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Plasma collection
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 4, 2026, 3:51 PM EDT
Completed Not applicable Interventional Results available

Low-dose Y90 Treatment Planning for HCC

NCT04172714
View directory record Official record
Conditions
HCC, Cancer of Liver, Cancer
Interventions
SIR-Spheres microspheres
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Sep 4, 2026, 3:51 PM EDT